Hellmann MD, Ott PA, Zugazagoitia J, et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. J Clin Oncol. 35, 2017 (suppl; abstr 8503).
Ontdekking target tripelnegatieve borstkanker opent deur voor nieuwe immuuntherapie
sep 2024 | Borstkanker, Immuuntherapie